Nvidia To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…
17 Analysts Have This To Say About Crinetics Pharmaceuticals
In the latest quarter, 17 analysts provided ratings for Crinetics Pharmaceuticals (NASDAQ:CRNX), showcasing a mix of bullish and…
Crinetics To Present New Data Results Of The Phase 3 PATHFNDR-2 Trial Showing Increasing Evidence Positioning Once-Daily, Oral Paltusotine As Potential First-Choice Treatment Option for Acromegaly At ENDO 2024
First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid and Sustained IGF-1 Responses in People Treated with Paltusotine New PATHFNDR-1
Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were slightly lower, with the Dow Jones index falling around 10 points on Wednesday. Shares of…
Crinetics Pharmaceuticals Announces ENDO 2024 Late-Breaking Abstracts; Were Released Earlier Than The Previously Announced Embargoed Date; More Fulsome Data Set Will Be Shared Within The Poster Presentations Scheduled To Be Presented On June 3, 2024
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors,
18 Analysts Have This To Say About Crinetics Pharmaceuticals
In the last three months, 18 analysts have published ratings on Crinetics Pharmaceuticals (NASDAQ:CRNX), offering a diverse range…
Crinetics Pharmaceuticals To Present Advancements From Atumelnant And Paltusotine Development Programs At ENDO 2024 June 1-4, 2024
Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings from Phase 1b/2a ACTH-Dependent Cushing's Syndrome Trial Data from Phase 3 PATHFNDR 1 and
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
12 Health Care Stocks Moving In Thursday’s Pre-Market Session
Gainers Cingulate (NASDAQ:CING) stock moved upwards by 188.5% to $11.51 during Thursday’s pre-market session. The market value of…
Endocrine Diseases-Focused Crinetics Pharmaceuticals Highlights Favorable Initial Findings From Mid-Stage Study
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) released initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound being developed for